ArticleEvolution, medicine, and public health2026
Competitive suppression and release in artemisinin-resistant
Article in Evolution, medicine, and public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Infection with multiple genetically distinct Methodology: Pairwise competitive growth outcomes of genetically distinct ART-resistant (ART-R) and ART-sensitive clones isolated from the Thailand-Myanmar border were evaluated after perturbation with dihydroartemisinin. Fluorescent labeled microsatellite markers were used to measure the relative growth densities of each competing parasite. Resistant and susceptible clones were mixed and grown alone in the presence and absence of drug to determine dynamic fitness relationships among the co-infecting parasites. Results: ART-R strains demonstrate a competitive advantage when grown in the presence of a high drug dose. However, the loss of this advantage varies in the absence of drug, producing a range of fitness phenotypes for sensitive and resistant strains. Conclusions and implications: Not surprisingly, drug-resistant parasites outcompete susceptible parasites under drug; however, additional variables influence whether resistant parasites ultimately prevail when drug is removed, suggesting independent or interacting genetic mechanisms. Knowing relative fitness advantages and costs of specific genotypes can inform how they will spread and evolve in a competitive environment, directing novel intervention strategies. Lay Summary: Malaria infections often contain both drug-resistant and drug-sensitive parasites. Parasites were co-grown with and without antimalarials and competitive outcomes varied: sometimes resistant parasites won, sometimes sensitives parasites won, and in one case, the winner changed with antimalarial treatment. Drug-resistant parasite success depends on competing parasites, complicating the prediction of resistance spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.